Novo Nordisk replaces Sanofi as the top marketer of metabolic drugs; Actavis changed its name to Allergan; access to Medicare Part D has not reduced overall Medicare costs
Five things for pharma marketers to know: Friday, May 1
Nexium tops the list of Medicare’s spending on brand drugs; Gilead Sciences doubles its first-quarter profit; Pfizer reportedly wants to buy a rare-disease drug company
Medicare shelled out more than $4.7 billion on hep C last year
March 30, 2015
7:00 pm
Key contributors to the total: Sovaldi, Harvoni and Olysio
Five things for pharma marketers to know: Tuesday, February 3
President Barack Obama states in budget proposal that government should negotiate drug pricing; J&J’s rare cancer drug’s review is expedited; inhalable insulin hits pharmacy shelves.
OIG: Crack down on Medicare co-pay cards
September 23, 2014
6:02 pm
The Office of the Inspector General says more needs to be done to keep Medicare patients from using the discount cards.
CMS backs off Part D revision
March 11, 2014
5:42 pm
The agency’s move to limit the formulary for certain drug classes is dead.
Proposed budget gets mixed reviews
March 5, 2014
7:00 pm
The White House’s proposed FY 2015 budget gives an additional 1% to the FDA.
Antidepressants may have to fight for Part D coverage
January 7, 2014
7:02 pm
CMS is proposing a rule that could change how antidepressants get on Medicare Part D formularies.
Study shows how brand Rx drain Medicare
November 20, 2013
7:25 pm
ProPublica’s deep-dive into Medicare brand-prescribing habits show brands make a dent in Medicare’s budget.
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix